/
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -35.01% to -37.98%, capital efficiency is deteriorating. Negative free cash flow of -$125M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$124M
▲ +17.4% YoY
Op. Margin
—
ROIC
-42.19%
▼ -3.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$126M
▲ +26.8% YoY
Op. Cash Flow (TTM)
-$126M
▲ +26.7% YoY
Net Debt
-$173M
Net Cash Position
Cash & Equiv.
$212M
Continue Research